Finally, genetic type I interferonopathies such as SAVI and AGS establish clear causality via constitutive pathway activation and respond to JAK inhibition, with next-generation cGAS–STING inhibitors emerging [93]. This evidence concerns the gene STING1 and STING-associated vasculopathy with onset in infancy.